Imaging of P‐glycoprotein–mediated pharmacoresistance in the hippocampus: Proof‐of‐concept in a chronic rat model of temporal lobe epilepsy

Abstract

These results constitute a proof-of-concept for a novel imaging approach to evaluate blood-brain barrier P-glycoprotein function in animals. By extension, [(18) F]MPPF positron emission tomography (PET) with tariquidar pretreatment may be amenable for clinical applications exploring further the relevance of P-glycoprotein overexpression, and for enabling the rational design of pharmacotherapy according to individual differences in P-glycoprotein expression.